KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to $77.1 million.

  • Inovio Pharmaceuticals' Total Liabilities rose 13003.31% to $77.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.1 million, marking a year-over-year increase of 13003.31%. This contributed to the annual value of $44.7 million for FY2024, which is 1662.03% down from last year.
  • According to the latest figures from Q3 2025, Inovio Pharmaceuticals' Total Liabilities is $77.1 million, which was up 13003.31% from $39.7 million recorded in Q2 2025.
  • In the past 5 years, Inovio Pharmaceuticals' Total Liabilities ranged from a high of $161.7 million in Q2 2022 and a low of $33.5 million during Q3 2024
  • In the last 5 years, Inovio Pharmaceuticals' Total Liabilities had a median value of $67.4 million in 2023 and averaged $72.7 million.
  • Per our database at Business Quant, Inovio Pharmaceuticals' Total Liabilities tumbled by 6757.0% in 2021 and then surged by 13003.31% in 2025.
  • Over the past 5 years, Inovio Pharmaceuticals' Total Liabilities (Quarter) stood at $96.3 million in 2021, then skyrocketed by 31.06% to $126.2 million in 2022, then plummeted by 57.52% to $53.6 million in 2023, then decreased by 16.62% to $44.7 million in 2024, then skyrocketed by 72.52% to $77.1 million in 2025.
  • Its Total Liabilities stands at $77.1 million for Q3 2025, versus $39.7 million for Q2 2025 and $36.0 million for Q1 2025.